Review
The clinical experience of antisense therapy to ICAM-1 in Crohn's disease
Affiliations
- PMID: 11713798
Item in Clipboard
Review
The clinical experience of antisense therapy to ICAM-1 in Crohn's disease
Curr Opin Mol Ther.
1999 Jun.
Abstract
ISIS-2302 is a 6781.24 amu molecular weight antisense molecule. Its sequence is 5'-GCCCAAGCTGGCATCCGTCA-3'. This 20 base phosphorothioate hybridizes to a sequence in the 3' untranslated region of human ICAM-1 mRNA. This substrate is cleaved by RNase H, resulting in specific message and protein reduction 11,21.
Similar articles
-
Amelioration of chronic and spontaneous intestinal inflammation with an antisense oligonucleotide (ISIS 9125) to intracellular adhesion molecule-1 in the HLA-B27/beta2 microglobulin transgenic rat model.J Pharmacol Exp Ther. 2002 Sep;302(3):908-17. doi: 10.1124/jpet.102.036053. J Pharmacol Exp Ther. 2002. PMID: 12183646
-
Alicaforsen. Isis Pharmaceuticals.Curr Opin Investig Drugs. 2001 Oct;2(10):1401-6. Curr Opin Investig Drugs. 2001. PMID: 11890355 Review.
-
Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.Clin Exp Immunol. 2005 Jul;141(1):141-7. doi: 10.1111/j.1365-2249.2005.02830.x. Clin Exp Immunol. 2005. PMID: 15958080 Free PMC article. Clinical Trial.
-
Technology evaluation: alicaforsen (Isis).Curr Opin Mol Ther. 2005 Jun;7(3):273-81. Curr Opin Mol Ther. 2005. PMID: 15977426 Review.
-
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.Gut. 2002 Jul;51(1):30-6. doi: 10.1136/gut.51.1.30. Gut. 2002. PMID: 12077088 Free PMC article. Clinical Trial.
Cited by
-
Functionally enhanced siRNA targeting TNFα attenuates DSS-induced colitis and TLR-mediated immunostimulation in mice.Mol Ther. 2012 Feb;20(2):382-90. doi: 10.1038/mt.2011.236. Epub 2011 Nov 1. Mol Ther. 2012. PMID: 22044934 Free PMC article.
-
Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension.Mol Diagn Ther. 2022 Jan;26(1):117-127. doi: 10.1007/s40291-021-00573-z. Epub 2022 Jan 7. Mol Diagn Ther. 2022. PMID: 34994962 Free PMC article.
-
Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.Nucleic Acids Res. 2016 Mar 18;44(5):2093-109. doi: 10.1093/nar/gkv1210. Epub 2015 Nov 8. Nucleic Acids Res. 2016. PMID: 26553810 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous